On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...